Lam Research stock dips today — what traders watch before LRCX earnings next week

Lam Research stock dips today — what traders watch before LRCX earnings next week

New York, Jan 23, 2026, 11:46 (ET) — Regular session

Shares of Lam Research slipped $1.50, or 0.7%, to $219.20 during late morning trading on Friday.

The chip-equipment maker’s shares have been sliding ahead of its upcoming update. Lam Research has set its December-quarter earnings call for Jan. 28. (Lam Research Investor Relations)

The scene is volatile. Intel’s weak outlook dragged chip stocks down and sharpened focus on company forecasts, with investors also eyeing next week’s Federal Reserve meeting for hints on interest rates. “Guidance now is more critical than ever,” said Peter Cardillo, chief market economist at Spartan Capital Securities. (Reuters)

Lam dropped 3.4% Thursday, closing at $220.70, despite gains in the broader U.S. market. The stock remains 5.2% shy of its 52-week peak of $232.90, reached just a day before. (MarketWatch)

Several analysts have taken advantage of the recent pullback to increase their stakes ahead of earnings. Citi lifted its price target on Lam to $265 from $190, maintaining a buy rating. The firm dubbed Lam a “Phase 2 upcycle” play, as spending on wafer-fab equipment—the tools chipmakers use to build semiconductors—edges closer to its $126 billion bull case for 2026. (TipRanks)

Deutsche Bank’s Melissa Weathers bumped her price target for Lam to $260 from $195, maintaining a buy rating. The firm expects Lam’s upcoming results to come in well above consensus estimates — with “Street” referring to the average analyst forecast. (TipRanks)

Friday’s session saw a mixed bag among peers. Applied Materials gained roughly 1%, KLA held steady, while ASML dipped around 0.7%.

Lam supplies deposition, etch, and cleaning equipment for chip production. Its sales closely track customers’ capital expenditures, which can shift quickly—particularly as memory manufacturers adjust their budgets up or down.

But the setup goes both ways. A weaker forecast for orders or margins could weigh on the stock fast, while any change to U.S. chip-tool export policies would bring fresh uncertainty to the table.

Lam is set to release its earnings report after the market closes on Jan. 28. (Nasdaq)

Stock Market Today

  • 10x Genomics (TXG) Stock Valuation Examined After Sharp Price Gains
    January 23, 2026, 12:15 PM EST. 10x Genomics (TXG) has seen a recent share price surge with a 40.55% increase over one month and a 68.41% rise in 90 days, driven by investor interest in genomics tools. Despite this momentum, the stock trades at $23.19, above the average analyst price target of $18.23 and a narrative-based fair value of $17.36, suggesting possible overvaluation. The company's acquisition of Scale Biosciences enhances its single-cell analysis capabilities, potentially boosting future revenue and margins. Risks remain, including reduced research funding and pricing pressures that may affect growth expectations. Investors are urged to weigh these factors as 10x Genomics' long-term total shareholder returns have been weaker. The stock's elevated price demands careful consideration of the underlying growth story and market assumptions.
Robinhood stock rises on MIAXdx deal closure — what traders watch next
Previous Story

Robinhood stock rises on MIAXdx deal closure — what traders watch next

Visa stock inches up as traders eye Jan. 29 earnings and UK fee-cap risk
Next Story

Visa stock inches up as traders eye Jan. 29 earnings and UK fee-cap risk

Go toTop